{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:51:55Z","timestamp":1789213915858,"version":"build-2803163510"},"reference-count":20,"publisher":"American Academy of Pediatrics (AAP)","issue":"Supplement_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3,1]]},"abstract":"<jats:p>Until recently, medical management of osteogenesis imperfecta, a genetic disorder of reduced bone mass and frequent fractures, was elusive, and treatment was focused on maximizing mobility and function. The introduction of bisphosphonates for the treatment of osteogenesis imperfecta 14 years ago changed this paradigm. Cyclic intravenous pamidronate therapy leads to an increase in bone density and a decrease in fracture rate in patients with osteogenesis imperfecta. Pamidronate therapy has a positive impact on functional parameters including improved energy, decreased bone pain, and increased ambulation. Histomorphometric studies have shown that the reduced osteoclast activity results in gains in cortical thickness and trabecular bone volume. Potential negative effects may include prolonged time to heal after osteotomies and a decrease in the rate of bone remodeling. Overall, it seems clear that the benefits of pamidronate therapy outweigh its potential risks in moderate-to-severe osteogenesis imperfecta, and pamidronate therapy has become the standard of care for patients with this condition. Questions remain regarding when treatment should be stopped and the need for pamidronate therapy in patients with mild osteogenesis imperfecta.<\/jats:p>","DOI":"10.1542\/peds.2006-2023i","type":"journal-article","created":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T02:35:04Z","timestamp":1172802904000},"page":"S163-S165","source":"Crossref","is-referenced-by-count":81,"title":["Experience With Bisphosphonates in Osteogenesis Imperfecta"],"prefix":"10.1542","volume":"119","author":[{"given":"Francis H.","family":"Glorieux","sequence":"first","affiliation":[{"name":"Genetics Unit, Shriners Hospital for Children and McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2007,3,1]]},"reference":[{"key":"2021120820595019700_R1","doi-asserted-by":"crossref","unstructured":"Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet.\u20082004;363:1377\u20131385","DOI":"10.1016\/S0140-6736(04)16051-0"},{"key":"2021120820595019700_R2","doi-asserted-by":"crossref","unstructured":"Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone.\u20082000;26:581\u2013589","DOI":"10.1016\/S8756-3282(00)00269-6"},{"key":"2021120820595019700_R3","doi-asserted-by":"crossref","unstructured":"Glorieux FH, Bishop NJ, Plotkin, H, Chabot G, Lanoue G, Travers R. Cyclical administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med.\u20081998;339:947\u2013952","DOI":"10.1056\/NEJM199810013391402"},{"key":"2021120820595019700_R4","doi-asserted-by":"crossref","unstructured":"Montpetit K, Plotkin H, Rauch F, et al. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics.\u20082003;111(5). Available at: www.pediatrics.org\/cgi\/content\/full\/111\/5\/e601","DOI":"10.1542\/peds.111.5.e601"},{"key":"2021120820595019700_R5","doi-asserted-by":"crossref","unstructured":"Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res.\u20082003;18:610\u2013614","DOI":"10.1359\/jbmr.2003.18.4.610"},{"key":"2021120820595019700_R6","doi-asserted-by":"crossref","unstructured":"Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone.\u20082006;39:901\u2013906","DOI":"10.1016\/j.bone.2006.04.004"},{"key":"2021120820595019700_R7","doi-asserted-by":"crossref","unstructured":"Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab.\u20082000;85:1846\u20131850","DOI":"10.1210\/jcem.85.5.6584"},{"key":"2021120820595019700_R8","doi-asserted-by":"crossref","unstructured":"Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment in osteogenesis imperfecta. Arch Dis Child.\u20082002;86:356\u2013364","DOI":"10.1136\/adc.86.5.356"},{"key":"2021120820595019700_R9","doi-asserted-by":"crossref","unstructured":"Zacharin M, Batemen J. Pamidronate treatment of osteogenesis imperfecta: lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment. J Pediatr Endocrinol Metab.\u20082002;15:163\u2013174","DOI":"10.1515\/JPEM.2002.15.2.163"},{"key":"2021120820595019700_R10","doi-asserted-by":"crossref","unstructured":"Maasalu K, Haviko T, Martson A. Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr.\u20082003;92:452\u2013455","DOI":"10.1111\/j.1651-2227.2003.tb00577.x"},{"key":"2021120820595019700_R11","unstructured":"Glorieux FH, Rauch F, Ward LM, et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. J Bone Miner Res.\u20082004;19:S12"},{"key":"2021120820595019700_R12","doi-asserted-by":"crossref","unstructured":"Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr.\u20082006;148:456\u2013460","DOI":"10.1016\/j.jpeds.2005.10.041"},{"key":"2021120820595019700_R13","doi-asserted-by":"crossref","unstructured":"Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics.\u20082003;111:1030\u20131036","DOI":"10.1542\/peds.111.5.1030"},{"key":"2021120820595019700_R14","doi-asserted-by":"crossref","unstructured":"Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest.\u20082002;110:1293\u20131299","DOI":"10.1172\/JCI0215952"},{"key":"2021120820595019700_R15","doi-asserted-by":"crossref","unstructured":"Rauch R, Travers R, Munns CF, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res.\u20082004;19:1191\u20131193","DOI":"10.1359\/JBMR.040303"},{"key":"2021120820595019700_R16","doi-asserted-by":"crossref","unstructured":"Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res.\u20082004;19:1779\u20131786","DOI":"10.1359\/JBMR.040814"},{"key":"2021120820595019700_R17","doi-asserted-by":"crossref","unstructured":"Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone.\u20082000;27:687\u2013694","DOI":"10.1016\/S8756-3282(00)00376-8"},{"key":"2021120820595019700_R18","doi-asserted-by":"crossref","unstructured":"Boyde A, Travers R, Glorieux FH, Jones SJ. The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Calcif Tissue Int.\u20081999;64:185\u2013190","DOI":"10.1007\/s002239900600"},{"key":"2021120820595019700_R19","doi-asserted-by":"crossref","unstructured":"Weber M, Roschger P, Fratzl-Zelman N, et al. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone.\u20082006;39:616\u2013622","DOI":"10.1016\/j.bone.2006.02.071"},{"key":"2021120820595019700_R20","doi-asserted-by":"crossref","unstructured":"Munns CF, Rauch F, Ward LM, Glorieux FH. Maternal and fetal outcome following long term pamidronate treatment before conception: a report of two cases. J Bone Miner Res.\u20082004;19:1742\u20131745","DOI":"10.1359\/JBMR.040711"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/119\/Supplement_2\/S163\/889377\/zpe6030700s163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/119\/Supplement_2\/S163\/889377\/zpe6030700s163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:56:47Z","timestamp":1639011407000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/119\/Supplement_2\/S163\/29149\/Experience-With-Bisphosphonates-in-Osteogenesis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,1]]},"references-count":20,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2007,3,1]]},"published-print":{"date-parts":[[2007,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2006-2023i","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,1]]}}}